JP2011157403A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157403A5
JP2011157403A5 JP2011116366A JP2011116366A JP2011157403A5 JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5 JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
day
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011116366A
Other languages
English (en)
Japanese (ja)
Other versions
JP5623335B2 (ja
JP2011157403A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157403A publication Critical patent/JP2011157403A/ja
Publication of JP2011157403A5 publication Critical patent/JP2011157403A5/ja
Application granted granted Critical
Publication of JP5623335B2 publication Critical patent/JP5623335B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011116366A 1999-06-01 2011-05-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 Expired - Lifetime JP5623335B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13703899P 1999-06-01 1999-06-01
US60/137,038 1999-06-01
US18533600P 2000-02-29 2000-02-29
US60/185,336 2000-02-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000620987A Division JP4817503B2 (ja) 1999-06-01 2000-06-01 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012130177A Division JP2012176983A (ja) 1999-06-01 2012-06-07 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Division JP5960762B2 (ja) 1999-06-01 2014-08-18 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Publications (3)

Publication Number Publication Date
JP2011157403A JP2011157403A (ja) 2011-08-18
JP2011157403A5 true JP2011157403A5 (https=) 2012-07-26
JP5623335B2 JP5623335B2 (ja) 2014-11-12

Family

ID=26834850

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2000620987A Expired - Lifetime JP4817503B2 (ja) 1999-06-01 2000-06-01 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2007136041A Pending JP2007277253A (ja) 1999-06-01 2007-05-22 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2011116366A Expired - Lifetime JP5623335B2 (ja) 1999-06-01 2011-05-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2012130177A Pending JP2012176983A (ja) 1999-06-01 2012-06-07 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Expired - Lifetime JP5960762B2 (ja) 1999-06-01 2014-08-18 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2016060029A Withdrawn JP2016121184A (ja) 1999-06-01 2016-03-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000620987A Expired - Lifetime JP4817503B2 (ja) 1999-06-01 2000-06-01 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2007136041A Pending JP2007277253A (ja) 1999-06-01 2007-05-22 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012130177A Pending JP2012176983A (ja) 1999-06-01 2012-06-07 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Expired - Lifetime JP5960762B2 (ja) 1999-06-01 2014-08-18 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2016060029A Withdrawn JP2016121184A (ja) 1999-06-01 2016-03-24 Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Country Status (28)

Country Link
US (5) US6955810B2 (https=)
EP (3) EP1181054A1 (https=)
JP (6) JP4817503B2 (https=)
CN (1) CN1309419C (https=)
AU (2) AU783989B2 (https=)
BG (1) BG65579B1 (https=)
BR (1) BR0011250A (https=)
CA (1) CA2375827C (https=)
CY (1) CY1116042T1 (https=)
CZ (1) CZ300710B6 (https=)
DK (2) DK1488806T3 (https=)
EA (1) EA011384B1 (https=)
EE (1) EE200100651A (https=)
ES (2) ES2529706T3 (https=)
GE (1) GEP20063774B (https=)
HK (1) HK1043320A1 (https=)
HU (1) HUP0202568A3 (https=)
IL (2) IL146508A0 (https=)
IS (1) IS6179A (https=)
MX (1) MXPA01012388A (https=)
NO (1) NO20015864L (https=)
NZ (1) NZ515686A (https=)
PT (2) PT1488806E (https=)
SI (2) SI1488806T1 (https=)
SK (1) SK17232001A3 (https=)
TR (1) TR200103432T2 (https=)
WO (1) WO2000072881A1 (https=)
YU (1) YU85501A (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
DE60236735D1 (de) 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
WO2003068262A1 (en) * 2002-02-14 2003-08-21 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
CA2504125A1 (en) * 2002-11-01 2004-05-21 Boys Town National Research Hospital Inducible ligand for .alpha.1.beta.1 integrin and uses
WO2005004800A2 (en) * 2003-06-20 2005-01-20 Morehouse School Of Medicine Trypanosome derived apoptotic factors (taf)
US20080093950A1 (en) * 2003-12-09 2008-04-24 Electrotechnologies Selem. Inc Polyphase Claw-Pole Machines With a Segmented Magnetic Circuit
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
CA2723842A1 (en) * 2008-05-09 2009-11-12 Peter Vanlandschoot Amino acid sequences directed against integrins and uses thereof
EP2582391B1 (en) * 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
CN103370081A (zh) * 2011-02-03 2013-10-23 桑塔鲁斯股份有限公司 受试者的选择和治疗
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
MA49645A (fr) 2017-07-20 2021-03-31 Univ Virginia Patent Foundation Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US6111598A (en) 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HU220799B1 (hu) 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1995028961A1 (en) 1994-04-26 1995-11-02 Kanebo, Ltd. Remedy for rheumatoid arthritis
JPH08131185A (ja) * 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
FR2745912B1 (fr) * 1996-03-08 1998-05-29 Lorraine Laminage Procede et dispositif de controle de la soudabilite de toles sandwich
US6127524A (en) 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
HUP0202048A3 (en) 1998-05-22 2006-11-28 Boys Town Nat Res Hospital Oma Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
CA2340333A1 (en) 1998-10-06 2000-04-13 Biogen, Inc. Crystals of the alpha 1 beta 1 integrin i-domain and their use
PT1173201E (pt) * 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
EP1408839A1 (de) 1999-06-17 2004-04-21 Kai Dr. Desinger Chirurgische sonde zur minimal invasiven gewebeentnahme
WO2001073444A2 (en) 2000-03-28 2001-10-04 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
DE60236735D1 (de) 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
WO2003068262A1 (en) 2002-02-14 2003-08-21 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
PL2034830T3 (pl) 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
BR112012013093A2 (pt) 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
CN103370081A (zh) 2011-02-03 2013-10-23 桑塔鲁斯股份有限公司 受试者的选择和治疗
WO2013105161A1 (ja) 2012-01-11 2013-07-18 パナソニック株式会社 圧接型半導体装置及びその製造方法
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Similar Documents

Publication Publication Date Title
JP2011157403A5 (https=)
JP2022031635A5 (https=)
JP2013198490A5 (https=)
JP2014526898A5 (https=)
JP2012121878A5 (https=)
JP2010526028A5 (https=)
HRP20250807T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP2014110800A5 (https=)
JP2010536384A5 (https=)
JP2012070737A5 (https=)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2014205674A5 (https=)
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2021514973A5 (https=)
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
RU2016100892A (ru) Антитела против tweakr и их применение
NZ602040A (en) Anti-lrp6 antibodies
JP2014502955A5 (https=)
JP2014511179A5 (https=)
JP2010500371A5 (https=)
JP2017052784A5 (https=)
JP2016530223A5 (https=)
JP2006522830A5 (https=)
JP2018502060A5 (https=)